- Home
- ANAB vs SLQT Comparison
ANAB vs SLQT Comparison
Compare ANAB & SLQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- SLQT
- Stock Information
- Founded
- ANAB 2005
- SLQT 1999
- Country
- ANAB United States
- SLQT United States
- Employees
- ANAB N/A
- SLQT N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- SLQT Specialty Insurers
- Sector
- ANAB Health Care
- SLQT Finance
- Exchange
- ANAB Nasdaq
- SLQT Nasdaq
- Market Cap
- ANAB 759.5M
- SLQT 735.8M
- IPO Year
- ANAB 2017
- SLQT 2020
- Fundamental
- Price
- ANAB $18.59
- SLQT $4.57
- Analyst Decision
- ANAB Buy
- SLQT Hold
- Analyst Count
- ANAB 12
- SLQT 1
- Target Price
- ANAB $41.20
- SLQT $4.00
- AVG Volume (30 Days)
- ANAB 1.4M
- SLQT 3.1M
- Earning Date
- ANAB 03-10-2025
- SLQT 02-10-2025
- Dividend Yield
- ANAB N/A
- SLQT N/A
- EPS Growth
- ANAB N/A
- SLQT N/A
- EPS
- ANAB N/A
- SLQT N/A
- Revenue
- ANAB $57,172,000.00
- SLQT $1,456,941,000.00
- Revenue This Year
- ANAB $229.13
- SLQT $12.73
- Revenue Next Year
- ANAB N/A
- SLQT $14.03
- P/E Ratio
- ANAB N/A
- SLQT N/A
- Revenue Growth
- ANAB 282.17
- SLQT 25.67
- 52 Week Low
- ANAB $12.21
- SLQT $1.48
- 52 Week High
- ANAB $41.31
- SLQT $6.86
- Technical
- Relative Strength Index (RSI)
- ANAB 55.28
- SLQT 46.57
- Support Level
- ANAB $12.21
- SLQT $4.33
- Resistance Level
- ANAB $21.57
- SLQT $6.21
- Average True Range (ATR)
- ANAB 1.72
- SLQT 0.48
- MACD
- ANAB 0.39
- SLQT -0.02
- Stochastic Oscillator
- ANAB 68.16
- SLQT 17.74
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.